Skip to main content

Advertisement

Table 3 Anthropometric and metabolic variables and markers of endothelial function (n = 86)

From: Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial

  Baseline E2 E2+P P
Total-c (mg/dL) 216 ± 31a 207 ± 30b 203 ± 32b < 0.01
HDL-c (mg/dL) 63 ± 16 61 ± 15 61 ± 15 0.06
LDL-c (mg/dL) 129 ± 29a 123 ± 29a,b 119 ± 28b < 0.01
Triglycerides (mg/dL) 120 ± 53 115 ± 51 111 ± 53 0.2
Fast glucose (mg/dL) 91 ± 11 91 ± 8 92 ± 11 0.2
2h glucose (mg/dL) 103 ± 27 108 ± 36 105 ± 36 0.2
Insulin (μU/mL) 6.9 (3.9-9.7) 6.2 (2.8 -8.8) 6.9 (3.8 -9.1) 0.2
hsCRP (mg/L) 1.51 (0.38-2.9) 1.64 (0.4-3) 1.19 (0.3-2.1) 0.1
  1. Values expressed as median and interquartile range or mean ± SD. P = two-way analysis of variance with repeated measures (non parametric variables were log-converted for statistical analysis and reconverted for presentation in table format).
  2. Different superscript letters indicate statistical difference with Bonferroni multiple-comparison correction test (α < 5%).
  3. Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol + micronized progesterone.
  4. HDL-c high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein test, LDL-c low-density lipoprotein cholesterol, Total-c total lipoprotein cholesterol; 2h glucose: glucose levels 2 hours after 75g oral glucose load.